AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04578093 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LARC peer-based curriculum
Description: Peer-based educational videos and supplemental activities
Study NCT06460610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blow Bottle technique
Description: Patients sit at a table with comfortable position Hold the bottle with one hand and the tube with the other Put the tube in mouth by holding lips firmly Breath in through nose and out through mouth Blowing enough water is bubbled Short Breaks for 2 to 3 mints When mucus rises up get out of it by coughing or huffing
Study NCT06460610 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acapella along with Diaphragmatic Breathing
Description: Device which uses a counter weighted plug and magnet to create airway oscillations Acapella combines the effects of PEP therapy and airway vibrations and mobilize to clear pulmonary secretions Facilitates opening of airways in patients with lung disease. Patients instructions to close the mouth piece making surety to no leakage of air. Take a long breath in nose and blow out through the Acapella ,feel vibrations on chest. Duration of performing this technique 3 days a week for 20 mints per day, 4 weeks regular
Study NCT05537623 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe Alternatives for Teens and Youths (SAFETY)
Description: Please see description of experimental arm (arm one)
Study NCT05537623 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy
Description: Please see description of active comparator arm (arm two)
Study NCT05070234 — intervention group
Intervention type: GENETIC
Intervention: Blood collection for genetic analysis
Description: Genetic tests in this study are sequential testing, including MS-MLPA, whole exome sequencing, whole genome sequencing, as well as RNA-seq.
Study NCT05310747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Artwork present
Description: A virtual museum exhibit with a curated selection of artworks
Study NCT05310747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Artwork absent
Description: The same virtual museum exhibit space as the 'Artwork present' condition but with all of the artworks removed from the walls
Study NCT05310747 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Artwork absent
Description: The same virtual museum exhibit space as the 'Artwork present' condition but with all of the artworks removed from the walls
Study NCT05310747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social connection high
Description: Participants will identify a person from their life that makes them feel socially connected and then write (1) about that person and (2) an experience they had with that person that made them feel socially connected.
Study NCT05310747 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social connection low
Description: Participants will identify a person from their life that makes them feel socially disconnected and then write (1) about that person and (2) an experience they had with that person that made them feel socially disconnected.
Study NCT05310747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social connection low
Description: Participants will identify a person from their life that makes them feel socially disconnected and then write (1) about that person and (2) an experience they had with that person that made them feel socially disconnected.
Study NCT05961475 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fruit snack 1
Description: Fruit snacks with original level of sugar
Study NCT05961475 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fruit Snack 2
Description: Fruit snacks with original level of sugar and mulberry leaf extract
Study NCT05961475 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fruit Snack 3
Description: Fruit snacks with reduced level of sugar
Study NCT05961475 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fruit Snack 4
Description: Fruit snacks with zero added sugar
Study NCT05961475 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: White Bread
Description: White bread with matched carbohydrate as control
Study NCT05704777 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A 24-weeks concurrent exercise training program
Study NCT05704777 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Usual care
Study NCT06289686 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rotator cuff repairs with BioEnthesis augmentation
Description: Rotator cuff repair using BioEnthesis allograft patch
Study NCT06289686 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotator cuff repairs without BioEnthesis augmentation
Description: Rotator cuff repair using standard of care sutures and anchors
Study NCT06658886 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06247072 — intervention group
Intervention type: DEVICE
Intervention: Tonometer
Description: measures IOP
Study NCT04956627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986166
Description: Specified dose on specified days
Study NCT04956627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Specified dose on specified days
Study NCT04956627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Phenytoin Sodium
Description: Specified dose on specified days
Study NCT04956627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Description: Specified dose on specified days
Study NCT04984681 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: The traditional mindfulness intervention consists of the following: (1) orientation; (2) a series of eight weekly session of 2.5 to 3 hours; (3) a silent retreat during the between weeks 4 and 6; (4) daily home assignments including formal and informal mindfulness practices; and (5) didactic presentations on stress and the consequences of stress.
Study NCT04984681 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: The control condition will continue receiving usual care or standard of care.
Study NCT06619886 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous, engineered T Cells targeting TP53 R248Q
Description: TP53-R248Q mutant TCR-T Cells Injection, 28 days as a treatment cycle (cycle number N≤3), each cycle was divided into three D0, D7, D14 infusion, a total of 3 dose groups were set up, the single infusion of cells within the range of ±20% all meet the requirements
Study NCT06622954 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Protein- and Calorie restriction
Description: The intervention consists of 30% calorie and 70% protein restriction, based on their daily nutritional intake. The protein and calorie restriction will be given in the form of Scandishake from Nutricia. These are ready available and easy to tailor to the caloric and protein need of each individual study subject.
Study NCT06619028 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Weighted vest
Description: During the intervention period, the participants will be exposed to an external load, by means of a weighted vest of 10% of their body weight, for a minimum of 8 hours per day for 4 weeks. In the first phase of the study, participants will be followed without changes in their lifestyle as a control. During the intervention they will be instructed to perform their usual activities with the vest, without further alterations in their lifestyle. This will be followed by a 4-week follow-up period without the use of the weighted vest.
Study NCT06631326 — intervention group
Intervention type: PROCEDURE
Intervention: hepatic artery infusion chemotherapy
Description: Hepatic arterial infusion chemotherapy including FOLFOX and RALOX
Study NCT06631326 — intervention group
Intervention type: DRUG
Intervention: Lenvatinib + PD-1 monoclonal antibody
Description: PD-1 inhibitors including Camrelizumab, Sintilimab, Tislelizumab
Study NCT06718673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual delivery room visit
Description: The real-time labour room demonstration video aims to increase participants' awareness of the labour process, reduce unfamiliarity, and facilitate participation for pregnant women with access restrictions. Produced with a 360-degree camera, it shows detailed sections of the labour room, starting from the entrance. Key areas like birthing beds, toilets, bathrooms, and labour materials (mats, pilates balls, TVs) are highlighted. The video also covers baby cots and rest areas for attendants. Narrated by an experienced midwife, the video ensures patient privacy, no interventions, and excludes images or sounds of other pregnant women. Converted to 360-degree format, the video is available on YouTube for repeated viewing. (https://www.youtube.com/watch?v=EyCt-jTDCVs)
Study NCT06718673 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standart of care
Description: Pregnant women in the control group did not receive any intervention other than routine care and counselling.
Study NCT06709014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buntanetap/posiphen
Description: 30mg capsule by mouth once daily for 18 months
Study NCT06709014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule by mouth once daily for 18 months
Study NCT06721221 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point-by-point PVI with the QDot Micro catheter in QMODE+ setting with the Svtag software
Description: PVI will be performed via femoral access after transseptal puncture, guided by fluoroscopy pressure monitoring, intracardiac echocardiography (ICE) or transesophageal echocardiography (TEE). A fast anatomical left atrial map will be created; then, point-by-point PVI will be performed with QDot Micro catheter in QMODE plus with the Svtag software. Inter-tag distance should be ≤ 6 mm on the posterior wall and ≤ 4 mm on the anterior wall. All applications' duration should be 4 seconds. After creating the isolation circle, the presence or absence of first-pass isolation will be assessed on each side by the presence of entrance block. If PVI is complete, this is defined as first-pass isolation. If PVI is not complete at this point, touch-up lesions will be delivered to reach the isolation of all pulmonary veins. After that, acute PV reconnections will be evaluated during a 20 minutes waiting period.
Study NCT06729996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO)
Description: Subjects will take 30 mg tablet, once daily in the morning, taken with or without food for 12 weeks and after 12 weeks dose will be escalated to 45 mg based on Hemoglobin A1c (HbA1c) levels (HbA1c >7.0% at 12 weeks, escalate the dose) once daily in the morning, taken with or without food till 24 weeks.
Study NCT06729996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin (EMPA)
Description: Subjects will start with 10 mg dose, once daily in the morning, taken with or without food for 12 weeks and after 12 weeks dose will be escalated to 25 mg based on Hemoglobin A1c (HbA1c) levels (HbA1c >7.0% at 12 weeks, escalate the dose) once daily in the morning, taken with or without food.
Study NCT06731296 — intervention group
Intervention type: OTHER
Intervention: Presence of a risk factor
Description: Demographic, severity, type of surgery, diagnosis, diagnostic system, type of admission.
Study NCT06730737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video preventive education
Description: Interactive video that teaches the subject about the overall importance of prevention, smoking cessation, proper diet, exercise, and sleep.
Study NCT06731153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivarmacitinib
Description: a selective Janus kinase 1 inhibitor
Study NCT06731153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivarmacitinib
Description: a selective Janus kinase 1 inhibitor
Study NCT06731153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab (SHR-1210)
Description: a humanised anti-programmed death-1 (anti PD-1) antibody
Study NCT06731153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: Eribulin is an anticancer drug approved for treatment of metastatic breast cancer. This drug is a synthetic derivative from Japanese marine sponge Halichondria okadai. It acts by interfering with the microtubular growth ultimately leading to apoptosis after prolonged mitotic blockage.
Study NCT06731153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin is an anticancer drug approved for treatment of metastatic breast cancer. This drug is a synthetic derivative from Japanese marine sponge Halichondria okadai. It acts by interfering with the microtubular growth ultimately leading to apoptosis after prolonged mitotic blockage.
Study NCT06731569 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Advanced intelligence drill
Description: The AI drill is an innovative surgical tool designed specifically for Maxillary Sinus Floor Augmentation (MSFA) procedures. It incorporates advanced technology to enhance safety, precision, and efficiency during lateral window preparation.~It has an Automated Pressure-Sensing Mechanism which makes the drill automatically stops rotating when it detects contact with the Schneiderian membrane, minimizing the risk of perforation.~The OLA kit consists of Hydraulic Lift which is compatibility with the drill connected to a saline-filled syringe to gently elevate the Schneiderian membrane from the sinus floor.~It involves a Multi-Step Drilling Process using different drill tips designed each for a specific task including the pilot drill for initial window creation and the non-cutting ball-end drill for lateral wall thinning and smoothing.~It works at a controlled high-Speed Performance of 6000 RPM with irrigation system included.
Study NCT06731569 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional rotary instrument
Description: Traditional Rotary Drill~The traditional rotary drill is a commonly used surgical tool in Maxillary Sinus Floor Augmentation (MSFA) procedures, employing conventional drilling techniques for lateral window preparation. It is a widely recognized method due to its accessibility and effectiveness in skilled hands.~It Uses a rose-head bur attached to a surgical straight handpiece that operates at speeds of 800-1200 RPM with irrigation to prevent overheating and ensure efficient bone cutting.~It is a manual operator control that requires the surgeon's skill and experience to control the depth and force of drilling. And relies on visual and tactile feedback to identify when the Schneiderian membrane is close to exposure.~It is versatile and can be adapted to varying bone densities and anatomical complexities. It is effective for creating the window for sinus access.~It comes with an irrigation system to avoid necrosis of the bone.
Study NCT06730243 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retzius-sparing robot-assisted radical prostatectomy and Sandwich Technique of Total Urethral Reconstruction
Description: Retzius-sparing robot-assisted radical prostatectomy and Sandwich Technique of Total Urethral Reconstruction
Study NCT06730243 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Robot-Assisted Radical Prostatectomy
Description: Standard Robot-Assisted Radical Prostatectomy
Study NCT06730243 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Laparoscopic Radical Prostatectomy
Description: Laparoscopic Radical Prostatectomy
Study NCT06729541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multigenetic Pharmacogenomics-Guided Treatment (MPGT)
Description: In the guidance group, drug types and dosages were adjusted based on the results of Pharmacogenetic TESTING.
Study NCT06730542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib capsules will be self-administered orally by participants at a starting dose of 160 mg twice a day (BID) or 320 mg once a day (QD)\* at the beginning of Cycle 2 of Pola-R-CHP therapy.
Study NCT06730542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Participants will receive Methotrexate as per standard of care (SOC).
Study NCT06730542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Participants will receive Polatuzumab Vedotin as per standard of care (SOC).
Study NCT06730542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive Rituximab as per standard of care (SOC), as part of combination standard of care Pola-R-CHP therapy.
Study NCT06730542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Participants will receive Cyclophosphamide as per standard of care (SOC), as part of combination standard of care Pola-R-CHP therapy.
Study NCT06730542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Participants will receive Doxorubicin as per standard of care (SOC), as part of combination standard of care Pola-R-CHP therapy.
Study NCT06730542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will receive Prednisone as per standard of care (SOC), as part of combination standard of care Pola-R-CHP therapy.
Study NCT06731764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: Patients will receive Levothyroxine/Placebo~Levothyroxine/Liothyronine with Liothyronine administered twice daily.
Study NCT06731764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine
Description: Patients will receive Levothyroxine/Placebo~Levothyroxine/Liothyronine with Liothyronine administered twice daily.
Study NCT06731764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine/Liothyronine once daily
Description: Patients will receive Levothyroxine/Liothyronine with Liothyronine administered once daily;
Study NCT06731764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine/Liothyronine twice daily
Description: Patients will receive Levothyroxine/Liothyronine with Liothyronine administered twice daily;
Study NCT05452421 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isotonic carbohydrate beetroot juice drink
Description: An isotonic carbohydrate beetroot juice drink containing 141 mg nitrate per 100 ml (12.9 mmol). Total of 570 ml serving in two doses of 285 ml over one morning. Contains 6.2 g carbohydrate per 100 ml. Osmolality 304-310 mOsm/kg.
Study NCT05452421 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice drink
Description: A beetroot juice drink containing 141 mg nitrate per 100 ml (12.9 mmol). Total of 570 ml serving in two doses of 285 ml over one morning. Contains 6.1 g carbohydrate per 100 ml. Osmolality 390-410 mOsm/kg.
Study NCT06245967 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Frequency specific microcurrent therapy
Description: Concussion protocol
Study NCT06245967 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Frequency specific microcurrent therapy
Description: Shan concussion protocol
Study NCT04982016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: crystal therapy
Description: Infusion of 250ml crystal solution before anesthesia induction
Study NCT04982016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: colloid therapy
Description: Infusion of 250ml colloid solution before anesthesia induction
Study NCT05963828 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post-hospital management based on WeChat applet
Description: The brain and heart health manager uses the exclusive QR code in the WeChat applet to receive and manage patients. Patients can register and use the WeChat applet by scanning the QR code. The functions of WeChat applet include making medication plan for patients, daily medication reminder, targeted health education, health index monitoring, online consultation and so on.
Study NCT05963828 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Routine post-hospital follow-up management
Description: The brain and mental health managers routinely followed up the patients in the standard group for 1, 3, 6 and 12 months by telephone or outpatient follow-up, the main content of which was to inquire about the medication of patients and the management of stroke risk factors. Targeted health education was carried out according to the risk factors of patients.
Study NCT05654090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefoperazone sodium and sulbactam sodium
Description: Pharmacokinetic study under fasting conditions
Study NCT05654090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefoperazone sodium and sulbactam sodium
Description: Pharmacokinetic study under fasting conditions
Study NCT04799418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open Label Extension Study
Description: This study will investigate the safety and efficacy of extended treatments for the management of symptoms related to PD.
Study NCT05603156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: the usage of Olverembatinib combined with Inotuzumab Ozogamicin
Description: patients in this arm will accept a 28 days treatment regimen: Olverembatinib 40mg QOD (d1 to d28 )and Inotuzumab Ozogamicin 1.2mg/m2 (divided into 2 days, d1 and d8, 0.6mg/m2, respectively).
Study NCT04866433 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real-time binaural sound
Description: Play music with a frequency difference (real-time binaural sound) in each ear through headphones during sedation.